NCT02254707View on ClinicalTrials.gov

Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

April 30, 2006

Conditions
Hepatitis C, Chronic
Interventions
DRUG

BILB 1941 ZW

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02254707 - Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection | Biotech Hunter | Biotech Hunter